Oscar L Lopez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6485335/publications.pdf

Version: 2024-02-01

312 papers	44,580 citations	4388 86 h-index	2385 198 g-index
329 all docs	329 docs citations	329 times ranked	39585 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
2	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
3	Vascular Contributions to Cognitive Impairment and Dementia. Stroke, 2011, 42, 2672-2713.	2.0	2,989
4	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
5	Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2002, 288, 1475.	7.4	1,676
6	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
7	Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 233-239.	1.8	1,342
8	Practice guideline update summary: Mild cognitive impairment. Neurology, 2018, 90, 126-135.	1.1	1,263
9	Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1832.	7.4	1,064
10	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
11	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
12	Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2003, 60, 1385.	4.5	605
13	Brain structure and obesity. Human Brain Mapping, 2010, 31, 353-364.	3.6	555
14	<emph type="ital">Ginkgo biloba</emph> for Prevention of Dementia<subtitle>A Randomized Controlled Trial</subtitle>. JAMA - Journal of the American Medical Association, 2008, 300, 2253.	7.4	553
15	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	12.8	484
16	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
17	Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort. Journal of the American Geriatrics Society, 2005, 53, 1101-1107.	2.6	425
18	Physical activity predicts gray matter volume in late adulthood. Neurology, 2010, 75, 1415-1422.	1.1	414

#	Article	IF	Citations
19	Risk Factors for Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2003, 60, 1394.	4.5	406
20	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
21	Incidence and Prevalence of Dementia in the Cardiovascular Health Study. Journal of the American Geriatrics Society, 2004, 52, 195-204.	2.6	367
22	The Natural History of Alzheimer's Disease. Archives of Neurology, 1994, 51, 585.	4.5	359
23	Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53â€‰949). Molecular Psychiatry, 2015, 20, 183-192.	7.9	344
24	Mild Cognitive Impairment and Alzheimer Disease: Patterns of Altered Cerebral Blood Flow at MR Imaging. Radiology, 2009, 250, 856-866.	7.3	336
25	Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults. JAMA - Journal of the American Medical Association, 2015, 314, 781.	7.4	318
26	Amyloid imaging in mild cognitive impairment subtypes. Annals of Neurology, 2009, 65, 557-568.	5.3	309
27	Dissecting phenotypic traits linked to human resilience to Alzheimerâ€™s pathology. Brain, 2013, 136, 2510-2526.	7.6	294
28	<emph type="ital">Ginkgo biloba</emph> for Preventing Cognitive Decline in Older Adults<subtitle>A Randomized Trial</subtitle>. JAMA - Journal of the American Medical Association, 2009, 302, 2663.	7.4	286
29	The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. American Journal of Psychiatry, 2016, 173, 543-546.	7.2	279
30	Risk Factors for Dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology, 2003, 22, 13-22.	2.3	267
31	Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE Îµ4. Archives of Neurology, 2008, 65, 89-93.	4.5	263
32	Statin Use and the Risk of Incident Dementia. Archives of Neurology, 2005, 62, 1047.	4.5	261
33	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
34	Twenty-seven-year time trends in dementia incidence in Europe and the United States. Neurology, 2020, 95, e519-e531.	1.1	227
35	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology, 1999, 53, 1292-1292.	1.1	224
36	Evaluation of Dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology, 2003, 22, 1-12.	2.3	215

#	Article	IF	Citations
37	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
38	Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 310-314.	1.9	212
39	Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 600-607.	1.9	210
40	Psychiatric Symptoms Vary With the Severity of Dementia in Probable Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 346-353.	1.8	206
41	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
42	Age, Alzheimer disease, and brain structure. Neurology, 2009, 73, 1899-1905.	1.1	185
43	Differential Cortical Atrophy in Subgroups of Mild Cognitive Impairment. Archives of Neurology, 2005, 62, 1393.	4.5	183
44	A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1116-1121.	1.9	175
45	Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease. Archives of Neurology, 1999, 56, 1266.	4.5	173
46	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
47	Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiology of Aging, 2010, 31, 1326-1339.	3.1	170
48	Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology, 2005, 64, 1548-1552.	1.1	166
49	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved. Journal of Alzheimer's Disease, 2013, 34, 769-780.	2.6	164
50	Diagnosis of dementia. Neurology, 1989, 39, 76-76.	1.1	162
51	Pulse wave velocity is associated with Î²-amyloid deposition in the brains of very elderly adults. Neurology, 2013, 81, 1711-1718.	1.1	156
52	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
53	Arterial Stiffness and Î²-Amyloid Progression in Nondemented Elderly Adults. JAMA Neurology, 2014, 71, 562.	9.0	152
54	Research evaluation and diagnosis of probable Alzheimerâ€™s disease over the last two decades: I. Neurology, 2000, 55, 1854-1862.	1.1	150

#	Article	IF	Citations
55	Neuropsychological characteristics of mild cognitive impairment subgroups. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 159-165.	1.9	150
56	Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology, 2008, 70, 1664-1671.	1.1	148
57	Maintenance Treatment of Depression in Old Age. Archives of General Psychiatry, 2011, 68, 51.	12.3	145
58	Incidence of Dementia in Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study. Archives of Neurology, 2007, 64, 416.	4.5	144
59	Research Evaluation and Prospective Diagnosis of Dementia With Lewy Bodies. Archives of Neurology, 2002, 59, 43.	4.5	137
60	Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia. JAMA Neurology, 2017, 74, 1105.	9.0	136
61	GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Molecular Psychiatry, 2016, 21, 189-197.	7.9	134
62	Alzheimer's disease with delusions and hallucinations. Neurology, 1991, 41, 906-906.	1.1	132
63	Abnormal Regional Cerebral Blood Flow in Cognitively Normal Elderly Subjects With Hypertension. Stroke, 2008, 39, 349-354.	2.0	131
64	A Self-Report Risk Index to Predict Occurrence of Dementia in Three Independent Cohorts of Older Adults: The ANU-ADRI. PLoS ONE, 2014, 9, e86141.	2.5	121
65	Survival following dementia onset: Alzheimer's disease and vascular dementia. Journal of the Neurological Sciences, 2005, 229-230, 43-49.	0.6	120
66	Extrapyramidal Signs in Patients With Probable Alzheimer Disease. Archives of Neurology, 1997, 54, 969-975.	4.5	119
67	The effects of physical activity, education, and body mass index on the aging brain. Human Brain Mapping, 2011, 32, 1371-1382.	3.6	117
68	Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology, 2017, 88, 2089-2097.	1.1	117
69	Cerebral Ventricular Changes Associated With Transitions Between Normal Cognitive Function, Mild Cognitive Impairment, and Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, 14-24.	1.3	114
70	Research evaluation and diagnosis of possible Alzheimerâ€™s disease over the last two decades: II. Neurology, 2000, 55, 1863-1869.	1.1	112
71	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta inÂCognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2015, 23, 985-993.	1.2	112
72	Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society, 2005, 53, 83-87.	2.6	111

#	Article	IF	Citations
73	Genome-wide association study of Alzheimer's disease with psychotic symptoms. Molecular Psychiatry, 2012, 17, 1316-1327.	7.9	110
74	The Long-Term Effects of Conventional and Atypical Antipsychotics in Patients With Probable Alzheimerâ€™s Disease. American Journal of Psychiatry, 2013, 170, 1051-1058.	7.2	110
75	White matter lesions and brain gray matter volume in cognitively normal elders. Neurobiology of Aging, 2012, 33, 834.e7-834.e16.	3.1	107
76	Depressed Mood is Not a Risk Factor for Incident Dementia in a Community-Based Cohort. American Journal of Geriatric Psychiatry, 2009, 17, 653-663.	1.2	103
77	Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e1910319.	5.9	102
78	Three-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 97.	4.5	101
79	Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Molecular Psychiatry, 2015, 20, 594-601.	7.9	101
80	Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology, 2005, 64, 1539-1547.	1.1	99
81	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
82	Neuropathologic Correlates of Late-Onset Major Depression. Neuropsychopharmacology, 2004, 29, 2242-2250.	5.4	96
83	Patterns of Mild Cognitive Impairment After Treatment of Depression in the Elderly. American Journal of Geriatric Psychiatry, 2009, 17, 308-316.	1.2	96
84	Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology, 2002, 58, 907-911.	1.1	94
85	Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiology of Aging, 2007, 28, 389-397.	3.1	92
86	Reliability of NINDSâ€AIREN clinical criteria for the diagnosis of vascular dementia. Neurology, 1994, 44, 1240-1240.	1.1	92
87	Computed Tomography--but Not Magnetic Resonance Imaging--Identified Periventricular White-Matter Lesions Predict Symptomatic Cerebrovascular Disease in Probable Alzheimer's Disease. Archives of Neurology, 1995, 52, 659-664.	4.5	91
88	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2015, 14, 804-813.	10.2	91
89	In vivo assessment of amyloidâ€Î²2 deposition in nondemented very elderly subjects. Annals of Neurology, 2013, 73, 751-761.	5.3	89
90	Cerebral small vessel disease genomics and its implications across the lifespan. Nature Communications, 2020, 11, 6285.	12.8	89

#	Article	IF	Citations
91	Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 271-279.	0.8	86
92	Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Studyâ€“Cognition Study. Neurology, 2012, 79, 1599-1606.	1.1	86
93	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 139-148.	1.8	85
94	Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase, 2005, 11, 65-71.	0.6	84
95	Regular Fish Consumption and Age-Related Brain Gray Matter Loss. American Journal of Preventive Medicine, 2014, 47, 444-451.	3.0	82
96	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiology of Aging, 2015, 36, 1765.e7-1765.e16.	3.1	82
97	Subclinical Cardiovascular Disease and Death, Dementia, and Coronary Heart Disease in Patients 80+ Years. Journal of the American College of Cardiology, 2016, 67, 1013-1022.	2.8	82
98	Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk. NeuroImage, 2018, 172, 118-129.	4.2	82
99	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimer's and Dementia, 2020, 16, 1412-1425.	0.8	82
100	Amyloid-Î² Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. Journal of Alzheimer's Disease, 2015, 48, S151-S159.	2.6	80
101	Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. American Journal of Psychiatry, 1990, 147, 855-860.	7.2	79
102	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	4.4	79
103	Cognitive trajectories associated with Î²-amyloid deposition in the oldest-old without dementia. Neurology, 2013, 80, 1378-1384.	1.1	77
104	Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 921-932.	2.6	77
105	Predictors of progression in patients with AD and Lewy bodies. Neurology, 2000, 54, 1774-1779.	1.1	76
106	Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimer's and Dementia, 2013, 9, 338-345.	0.8	72
107	Event-related functional magnetic resonance imaging investigation of executive control in very old individuals with mild cognitive impairment. Biological Psychiatry, 2005, 57, 761-767.	1.3	71
108	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. JAMA Neurology, 2015, 72, 1021.	9.0	71

#	Article	IF	Citations
109	Reliability of NINCDSâ€ADRDA clinical criteria for the diagnosis of Alzheimer's disease. Neurology, 1990, 40, 1517-1517.	1.1	71
110	Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs. Alzheimer's and Dementia, 2014, 10, 409-415.	0.8	69
111	Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 123-130.	3.6	69
112	Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology, 2000, 54, 1780-1787.	1.1	68
113	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Biological Psychiatry, 2015, 77, 749-763.	1.3	67
114	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-Î² Concentrations and Cognition Outcomes inÂAlzheimerâ€™s Disease Patients: AÂMulticenter, Randomized, Controlled Clinical Trial. Journal of Alzheimer's Disease, 2017, 56, 129-143.	2.6	67
115	Association of Brain Amyloid-Î² With Slow Gait in Elderly Individuals Without Dementia. JAMA Neurology, 2017, 74, 82.	9.0	66
116	The apolipoprotein E Ïµ4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology, 1997, 49, 794-797.	1.1	65
117	The Psychotic Phenomenon in Probable Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 50-55.	1.8	64
118	Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study. Journal of Psychiatric Research, 2014, 49, 96-101.	3.1	64
119	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 61-69.	3.7	63
120	ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Molecular Psychiatry, 2014, 19, 682-687.	7.9	62
121	Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiology of Aging, 2014, 35, 802-807.	3.1	62
122	Relative ¹¹C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ¹⁵O-Water and ¹¹C-PiB PET. Journal of Nuclear Medicine, 2015, 56, 1199-1205.	5.0	62
123	Effect of Alzheimerâ€™s Disease Risk Genes on Trajectories of Cognitive Function in the Cardiovascular Health Study. American Journal of Psychiatry, 2012, 169, 954-962.	7.2	61
124	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nature Communications, 2020, 11, 4796.	12.8	61
125	Physical activity, body mass index, and brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2015, 36, S194-S202.	3.1	59
126	Neuropsychiatric Correlates of Cerebral White-Matter Radiolucencies in Probable Alzheimer's Disease. Archives of Neurology, 1992, 49, 828-834.	4.5	58

#	Article	IF	Citations
127	Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry. JAMA Network Open, 2019, 2, e191350.	5.9	58
128	ENGAGE and EMERGE: Truth and consequences?. Alzheimer's and Dementia, 2021, 17, 692-695.	0.8	58
129	EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology, 1997, 48, 1521-1525.	1.1	57
130	The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. International Psychogeriatrics, 2009, 21, 78.	1.0	57
131	Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health Study. American Journal of Geriatric Psychiatry, 2011, 19, 160-168.	1.2	57
132	Genetic data and cognitively defined late-onset Alzheimerâ€™s disease subgroups. Molecular Psychiatry, 2020, 25, 2942-2951.	7.9	57
133	Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features. International Psychogeriatrics, 2000, 12, 547-558.	1.0	56
134	Effect of S-equol and Soy Isoflavones on Heart and Brain. Current Cardiology Reviews, 2019, 15, 114-135.	1.5	56
135	Objective measures of physical activity, white matter integrity and cognitive status in adults over age 80. Behavioural Brain Research, 2015, 284, 51-57.	2.2	55
136	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	3.9	55
137	Genetic risk for schizophrenia and psychosis in Alzheimer disease. Molecular Psychiatry, 2018, 23, 963-972.	7.9	55
138	Physical activity, inflammation, and volume of the aging brain. Neuroscience, 2014, 273, 199-209.	2.3	53
139	Genetic Determinants of Disease Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 649-655.	2.6	53
140	Association of Thyroid Dysfunction With Cognitive Function. JAMA Internal Medicine, 2021, 181, 1440.	5.1	51
141	Markers of Cholesterol Metabolism in the Brain Show Stronger Associations with Cerebrovascular Disease than Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 53-61.	2.6	47
142	Pulmonary Function Impairment May Be an Early Risk Factor for Lateâ€Life Cognitive Impairment. Journal of the American Geriatrics Society, 2013, 61, 79-83.	2.6	47
143	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Molecular Psychiatry, 2021, 26, 309-321.	7.9	47
144	Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. PLoS Genetics, 2016, 12, e1006327.	3.5	47

#	Article	IF	Citations
145	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. Journal of Alzheimer's Disease, 2014, 39, 759-773.	2.6	46
146	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology, 2014, 83, 1804-1811.	1.1	46
147	Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. American Journal of Geriatric Psychiatry, 2006, 14, 352-360.	1.2	45
148	Evolution of the diagnostic criteria for degenerative and cognitive disorders. Current Opinion in Neurology, 2011, 24, 532-541.	3.6	45
149	Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging. Journal of Alzheimer's Disease, 2015, 49, 723-732.	2.6	45
150	Functional neuroimaging indicators of successful executive control in the oldest old. NeuroImage, 2005, 28, 881-889.	4.2	43
151	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.8	42
152	Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 710-717.	1.1	41
153	Vitamin D and Memory Decline: Two Population-Based Prospective Studies. Journal of Alzheimer's Disease, 2016, 50, 1099-1108.	2.6	41
154	Associations of fat and muscle tissue with cognitive status in older adults: the AGES-Reykjavik Study. Age and Ageing, 2017, 46, 250-257.	1.6	41
155	Late-life depression and increased risk of dementia: a longitudinal cohort study. Translational Psychiatry, 2021, 11, 147.	4.8	41
156	Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects.. Stroke, 1992, 23, 1078-1083.	2.0	40
157	Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiology of Aging, 2014, 35, 2021-2028.	3.1	40
158	Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. European Journal of Neurology, 2004, 11, 97-102.	3.3	39
159	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiology of Aging, 2015, 36, 2443.e21-2443.e26.	3.1	39
160	Direct Comparison of the Tau PET Tracers¹⁸F-Flortaucipir and¹⁸F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	5.0	39
161	Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2020, 78, 134-144.	5.8	38
162	Aortic Stiffness is Associated with Increased Risk of Incident Dementia in Older Adults. Journal of Alzheimer's Disease, 2018, 66, 297-306.	2.6	37

#	Article	IF	Citations
163	Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease. Neurology, 2006, 67, 660-665.	1.1	36
164	Mild Cognitive Impairment. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 411-424.	0.8	36
165	A genome-wide association meta-analysis of plasma AÎ² peptides concentrations in the elderly. Molecular Psychiatry, 2014, 19, 1326-1335.	7.9	36
166	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology, 2018, 90, e1920-e1928.	1.1	36
167	Predicting cognitive decline in Alzheimer's disease: An integrated analysis. Alzheimer's and Dementia, 2010, 6, 431-439.	0.8	34
168	Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1999, 12, 184-92.	0.4	34
169	Risk of dementia and death in the longâ€term followâ€up of the Pittsburgh Cardiovascular Health Studyâ€“Cognition Study. Alzheimer's and Dementia, 2016, 12, 170-183.	0.8	33
170	Amyloid Î² Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurology, 2018, 75, 88.	9.0	33
171	Ideomotor and ideational apraxia in alzheimer's disease. International Journal of Geriatric Psychiatry, 1993, 8, 413-417.	2.7	32
172	Genetic Variation in Imprinted Genes is Associated with Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 989-994.	2.6	32
173	Anxiety symptoms and risk of cognitive decline in older community-dwelling men. International Psychogeriatrics, 2017, 29, 1137-1145.	1.0	32
174	Initial Experience in Using Continuous Arterial Spin-Labeled MR Imaging for Early Detection of Alzheimer Disease. American Journal of Neuroradiology, 2010, 31, 847-855.	2.4	31
175	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. Nature Communications, 2018, 9, 3945.	12.8	31
176	Sleep moderates the relationship between amyloid beta and memory recall. Neurobiology of Aging, 2018, 71, 142-148.	3.1	31
177	Focal Atrophy and Cerebrovascular Disease Increase Dementia Risk among Cognitively Normal Older Adults. Journal of Neuroimaging, 2007, 17, 148-155.	2.0	30
178	Physical activity predicts reduced plasma Î² amyloid in the Cardiovascular Health Study. Annals of Clinical and Translational Neurology, 2017, 4, 284-291.	3.7	30
179	Anxiety symptoms and risk of dementia and mild cognitive impairment in the oldest old women. Aging and Mental Health, 2018, 22, 474-482.	2.8	30
180	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	7.9	30

#	Article	IF	Citations
181	Neurological complications after liver retransplantation. Hepatology, 1992, 16, 162-166.	7.3	29
182	Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1779.e15-1779.e16.	3.1	28
183	Clinical symptoms in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 207-216.	1.8	27
184	Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw155.	3.6	27
185	A genome-wide association study identifies genetic loci associated with specific lobar brain volumes. Communications Biology, 2019, 2, 285.	4.4	27
186	Estrogen, brain structure, and cognition in p<scp>ostmenopausal</scp> women. Human Brain Mapping, 2021, 42, 24-35.	3.6	27
187	Prediction of psychosis onset in Alzheimer disease: The role of depression symptom severity and the HTR2A T102C polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1054-1062.	1.7	26
188	Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease. Molecular and Cellular Proteomics, 2016, 15, 2252-2262.	3.8	26
189	Cerebral Blood Flow Is Associated with Diagnostic Class and Cognitive Decline in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1103-1120.	2.6	26
190	Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimerâ€™s Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study. Journal of Alzheimer's Disease, 2021, 82, 293-305.	2.6	26
191	Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. NeuroImage: Clinical, 2015, 9, 479-483.	2.7	25
192	Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimerâ€™s Disease. American Journal of Psychiatry, 2018, 175, 999-1009.	7.2	25
193	Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 2018, 91, 373-374.	1.1	25
194	Acceleration of cerebral ventricular expansion in the Cardiovascular Health Study. Neurobiology of Aging, 2007, 28, 1316-1321.	3.1	24
195	Psychosis in Alzheimer's Disease in the National Alzheimer's Disease Coordinating Center Uniform Data Set: Clinical Correlates and Association with Apolipoprotein E. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	2.0	24
196	Genome-wide copy-number variation study of psychosis in Alzheimerâ€™s disease. Translational Psychiatry, 2015, 5, e574-e574.	4.8	24
197	Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimerâ€™s Disease. Journal of Clinical Psychiatry, 2016, 77, e1564-e1569.	2.2	24
198	Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. European Journal of Epidemiology, 2017, 32, 931-938.	5.7	23

#	Article	IF	Citations
199	Spectrum of tau pathologies in Huntington's disease. Laboratory Investigation, 2019, 99, 1068-1077.	3.7	23
200	Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. JAMA Network Open, 2020, 3, e209250.	5.9	23
201	Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. Transplantation Proceedings, 1991, 23, 3181-2.	0.6	23
202	Psychiatric correlates of MR deep white matter lesions in probable Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 1997, 9, 246-250.	1.8	22
203	Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimerâ€™s Disease: Comparison of Efficacy and Effectiveness Studies. Neurodegenerative Diseases, 2012, 10, 170-174.	1.4	22
204	Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-Î² in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189.	4.1	22
205	Effectiveness and Safety of Donepezil in Hispanic Patients with Alzheimerâ€™s Disease: A 12-Week Open-Label Study. Journal of the National Medical Association, 2008, 100, 1350-1358.	0.8	21
206	Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14Âyears in older adults. Neurobiology of Aging, 2015, 36, 3038-3044.	3.1	21
207	Fetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis, 2015, 243, 44-52.	0.8	21
208	Longitudinal Relationships between Caloric Expenditure and Gray Matter in the Cardiovascular Health Study. Journal of Alzheimer's Disease, 2016, 52, 719-729.	2.6	21
209	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	5.0	21
210	The growing burden of Alzheimer's disease. American Journal of Managed Care, 2011, 17 Suppl 13, S339-45.	1.1	21
211	Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 167-178.	2.6	20
212	Tau Platelets Correlate with Regional BrainÂAtrophy in Patients with Alzheimerâ€™sÂDisease. Journal of Alzheimer's Disease, 2016, 55, 1595-1603.	2.6	19
213	Apolipoproteins and Alzheimer's pathophysiology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 545-553.	2.4	19
214	A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, 1330-1337.	0.8	19
215	Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study. Aging and Mental Health, 2009, 13, 171-182.	2.8	18
216	No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiology of Aging, 2011, 32, 555.e9-555.e11.	3.1	18

#	Article	IF	Citations
217	Dyadic Analysis of Illness Perceptions Among Persons with Mild Cognitive Impairment and Their Family Members. Gerontologist, The, 2016, 56, 886-895.	3.9	18
218	Inclusion of African American/Black adults in a pilot brain proteomics study of Alzheimer's disease. Neurobiology of Disease, 2020, 146, 105129.	4.4	18
219	Whole-Exome Sequencing Analysis of Alzheimerâ€™s Disease in Non-APOE*4 Carriers. Journal of Alzheimer's Disease, 2020, 76, 1553-1565.	2.6	18
220	Material-specific memory loss in probable Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1177-1181.	1.9	17
221	Fast 3D fluid registration of brain magnetic resonance images. , 2008, 6916, .		17
222	APOE DNA methylation is altered in Lewy body dementia. Alzheimer's and Dementia, 2018, 14, 889-894.	0.8	17
223	Problemâ€solving therapy reduces subjective burden levels in caregivers of family members with mild cognitive impairment or earlyâ€stage dementia: Secondary analysis of a randomized clinical trial. International Journal of Geriatric Psychiatry, 2019, 34, 957-965.	2.7	17
224	Neuropsychological, neuropsychiatric, and qualityâ€ofâ€life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. Alzheimer's and Dementia, 2022, 18, 1314-1324.	0.8	17
225	Telephone Interview for Cognitive Status. Neuroepidemiology, 2010, 34, 63-64.	2.3	16
226	A Rare Duplication on Chromosome 16p11.2 Is Identified in Patients with Psychosis in Alzheimer's Disease. PLoS ONE, 2014, 9, e111462.	2.5	16
227	Inflammatory Biomarkers and Cognitive Decline: The Ginkgo Evaluation of Memory Study. Journal of the American Geriatrics Society, 2016, 64, 1171-1177.	2.6	16
228	Slow gait, white matter characteristics, and prior 10-year interleukin-6 levels in older adults. Neurology, 2016, 87, 1993-1999.	1.1	16
229	Why Inclusion Matters for Alzheimerâ€™s Disease Biomarker Discovery in Plasma. Journal of Alzheimer's Disease, 2021, 79, 1327-1344.	2.6	16
230	Relationship between Systemic and Cerebral Vascular Disease and Brain Structure Integrity in Normal Elderly Individuals. Journal of Alzheimer's Disease, 2015, 44, 319-328.	2.6	15
231	High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. Journal of Lipid Research, 2020, 61, 445-454.	4.2	15
232	Hippocampal sclerosis, TDPâ€43, and the duration of the symptoms of dementia of AD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1546-1556.	3.7	15
233	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiology of Aging, 2020, 94, 111-120.	3.1	15
234	Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease. Blood, 2021, 138, 5-5.	1.4	15

#	Article	IF	Citations
235	Patterns of Compensation and Vulnerability in Normal Subjects at Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S427-S438.	2.6	14
236	Statins and brain integrity in older adults: Secondary analysis ofÂtheÂHealth ABC study. Alzheimer's and Dementia, 2015, 11, 1202-1211.	0.8	14
237	Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis. Alzheimer's and Dementia, 2019, 15, 1029-1038.	0.8	14
238	Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology, 2020, 95, e984-e994.	1.1	14
239	Orthostatic hypotension, dizziness, neurology outcomes, and death in older adults. Neurology, 2020, 95, e1941-e1950.	1.1	14
240	TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. International Psychogeriatrics, 2014, 26, 987-994.	1.0	13
241	Brain Volume as an Integrated Marker for the Risk of Death in a Community-Based Sample: Age Gene/Environment Susceptibilityâ€"Reykjavik Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 131-137.	3.6	13
242	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of AÎ² load. NeuroImage: Clinical, 2018, 19, 182-189.	2.7	13
243	Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients. American Journal of Geriatric Psychiatry, 2019, 27, 908-917.	1.2	13
244	Associations of body composition with incident dementia in older adults: Cardiovascular Health Studyâ€Cognition Study. Alzheimer's and Dementia, 2020, 16, 1402-1411.	0.8	13
245	Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiology, 2014, 28, 236-257.	2.2	12
246	Vitamin D and Risk of Neuroimaging Abnormalities. PLoS ONE, 2016, 11, e0154896.	2.5	12
247	Subclinical Atherosclerosis, Cardiac and Kidney Function, Heart Failure, and Dementia in the Very Elderly. Journal of the American Heart Association, 2017, 6, .	3.7	12
248	HIV infection and age effects on striatal structure are additive. Journal of NeuroVirology, 2019, 25, 480-495.	2.1	12
249	Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study. Alzheimer's and Dementia, 2023, 19, 549-559.	0.8	12
250	Patterns of Change in the Treatment of Psychiatric Symptoms in Patients With Probable Alzheimer's Disease From 1983 to 2000. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 67-73.	1.8	10
251	Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 542-555.	3.7	10
252	Associations of equolâ€producing status with white matter lesion and amyloidâ€Î² deposition in cognitively normal elderly Japanese. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12089.	3.7	10

#	Article	IF	Citations
253	Relationship of amyloid-Î²1â€“42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. Brain Communications, 2020, 2, fcz038.	3.3	10
254	Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries. Frontiers in Neurology, 2021, 12, 663407.	2.4	10
255	Speech motor control disorder after HIV infection. Neurology, 1994, 44, 2187-2187.	1.1	10
256	Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 413-420.	2.4	9
257	Association of Serum Neurofilament Light Chain Concentration and MRI Findings in Older Adults. Neurology, 2022, 98, .	1.1	9
258	The Effect of the <scp>APOE Îµ2Îµ4</scp> Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Nonâ€Latino Whites. Journal of the American Geriatrics Society, 2020, 68, 1044-1049.	2.6	8
259	11C-PiB PET can underestimate brain amyloid-Î² burden when cotton wool plaques are numerous. Brain, 2022, 145, 2161-2176.	7.6	8
260	Methodological considerations in estimating speed of cognitive operations. Journal of the International Neuropsychological Society, 1995, 1, 3-9.	1.8	7
261	Gene-Environment Interactions With Cognition in Late Life and Compression of Morbidity. American Journal of Psychiatry, 2007, 164, 849-852.	7.2	7
262	Use of Cardiac Implantable Electronic Devices in Older Adults With Cognitive Impairment. JAMA Internal Medicine, 2014, 174, 1514.	5.1	7
263	Empirically Derived Trajectories to Dementia Over 15 Years of Follow-up Identified by Using Mixed Membership Models. American Journal of Epidemiology, 2015, 182, 366-374.	3.4	7
264	Case-cohort study of plasma phospholipid fatty acid profiles, cognitive function, and risk of dementia: a secondary analysis in the Ginkgo Evaluation of Memory Study. American Journal of Clinical Nutrition, 2021, 114, 154-162.	4.7	7
265	Cardiovascular disease and dementia risk: an ever growing problem in an aging population. Expert Review of Cardiovascular Therapy, 2016, 14, 771-773.	1.5	6
266	Vascular disease and cerebral amyloid deposition. Neurology, 2018, 90, 635-636.	1.1	6
267	Highâ€dimensional longitudinal classification with the multinomial fused lasso. Statistics in Medicine, 2019, 38, 2184-2205.	1.6	6
268	Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence. European Neurological Journal, 2011, 3, 15-19.	0.0	6
269	Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate. Brain, 2022, 145, 1992-2007.	7.6	6
270	Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials, 2011, 12, 233.	1.6	5

#	Article	IF	Citations
271	Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease. Journal of Aging Research, 2014, 2014, 1-8.	0.9	5
272	The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. American Journal of Geriatric Psychiatry, 2018, 26, 977-984.	1.2	5
273	Preventing disability in older adults with mild cognitive impairment: A Strategy Training intervention study. Contemporary Clinical Trials Communications, 2019, 15, 100368.	1.1	5
274	Targeted Lipidomics To Measure Phospholipids and Sphingomyelins in Plasma: A Pilot Study To Understand the Impact of Race/Ethnicity in Alzheimerâ€™s Disease. Analytical Chemistry, 2022, 94, 4165-4174.	6.5	5
275	Development of Subtle Neurological Signs after Systemic Illness in HIV-infected Individuals. European Neurology, 1996, 36, 71-75.	1.4	4
276	Diagnosis, risk factors, and treatment of vascular dementia. Current Neurology and Neuroscience Reports, 2004, 4, 358-367.	4.2	4
277	Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 515-523.	3.7	4
278	Differential Effects of AIDS and Chronic Human Immunodeficiency Virus Infection on Gray Matter Volume. Clinical Infectious Diseases, 2021, 73, e2303-e2310.	5.8	4
279	Examining the Causal Mediating Role of Brain Pathology on the Relationship Between Diabetes and Cognitive Impairment: The Cardiovascular Health Study. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 1705-1726.	1.1	4
280	Alcohol Consumption, Brain Amyloid-Î² Deposition, and Brain Structural Integrity Among Older Adults Free of Dementia. Journal of Alzheimer's Disease, 2020, 74, 509-519.	2.6	4
281	Dementia and Alzheimerâ€™s Disease. , 2012, , 561-582.		4
282	Creutzfeldt-Jakob disease with features of obsessive-compulsive disorder and anorexia nervosa: the role of cortical-subcortical systems. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1997, 10, 120-4.	0.4	4
283	Preventing Dementia in Older Cardiovascular Patients. Current Cardiovascular Risk Reports, 2014, 8, 1.	2.0	3
284	Cerebral bleed after shunt for normal pressure hydrocephalus with cerebral amyloid angiopathy. Neurology: Clinical Practice, 2015, 5, 263-266.	1.6	3
285	The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults. International Psychogeriatrics, 2020, 33, 1-12.	1.0	3
286	Hemostatic factor levels and cognitive decline in older adults: The Cardiovascular Health Study. Journal of Thrombosis and Haemostasis, 2021, 19, 1219-1227.	3.8	3
287	Psychosis in Alzheimer's Disease Is Associated With Increased Excitatory Neuron Vulnerability and Post-transcriptional Mechanisms Altering Synaptic Protein Levels. Frontiers in Neurology, 2022, 13, 778419.	2.4	3
288	Association of Peripheral Lymphocyte Subsets with Cognitive Decline and Dementia: The Cardiovascular Health Study. Journal of Alzheimer's Disease, 2022, 88, 7-15.	2.6	3

#	Article	IF	Citations
289	Mechanism of the Effect of Constant Infusion of Epinephrine on Blood Pressure, Heart Rate and Arterial Hematocrit in Normal and Sympathectomized-Splanchnicectomized Dogs. Archives Internationales De Physiologie Et De Biochimie, 1960, 68, 785-792.	0.2	2
290	RESPONSE LETTER TO DR. THOMAS FINUCANE. Journal of the American Geriatrics Society, 2005, 53, 1831-1833.	2.6	2
291	Chapter 2 Alzheimer's Disease. Blue Books of Neurology, 2007, , 33-58.	0.1	2
292	Sex Differences in the Association Between Pentraxin 3 and Cognitive Decline: The Cardiovascular Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1523-1529.	3.6	2
293	Brachial Flow-mediated Dilation and Risk of Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 272-274.	1.3	2
294	Association Between the APOE É›2/É›4 Genotype and Alzheimerâ€™s Disease and Mild Cognitive Impairment Among African Americans. Journal of Alzheimer's Disease, 2021, 81, 943-948.	2.6	2
295	Cardiovascular damage phenotypes and all-cause and CVD mortality in older adults. Annals of Epidemiology, 2021, 63, 35-40.	1.9	2
296	Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90+. Alzheimer's and Dementia, 2022, , .	0.8	2
297	Association of low-frequency and rare coding variants with information processing speed. Translational Psychiatry, 2021, 11, 613.	4.8	2
298	Genome-Wide Association Study of Incident Dementia in a Community-Based Sample of Older Subjects. Journal of Alzheimer's Disease, 2022, 88, 787-798.	2.6	2
299	Commentary on â€œVascular cognitive impairment: Today and tomorrowâ€• , 2006, 2, 200-201.		1
300	Progression to Dementia in Probable and Possible Mild Cognitive Impairmentâ€”Reply. Archives of Neurology, 2007, 64, 1210.	4.5	1
301	Dataset of why inclusion matters for Alzheimer's disease biomarker discovery in plasma. Data in Brief, 2021, 35, 106923.	1.0	1
302	Prognostic accuracy for predicting ordinal competing risk outcomes using ROC surfaces. Lifetime Data Analysis, 2021, 28, 1.	0.9	1
303	Standardization and diagnostic utility of the Frontal Assessment Battery for healthy people and patients with dementia in the Chilean population. Dementia E Neuropsychologia, 2022, 16, 69-78.	0.8	1
304	Revisiting Purine Nucleoside Cholinesterase Inhibitors - An Experimental Glycon Structure/Activity Relationship Study. Medicinal Chemistry, 2023, 19, 263-275.	1.5	1
305	S4-01-04: Amyloid imaging in the 80+ population and cognitive trajectories (GEMS). , 2015, 11, P257-P258.		0
306	[O4â€“07â€“03]: AMYLOID DEPOSITION AND BRAIN STRUCTURE AS LONGâ€TERM PREDICTORS OF DEMENTIA IN COGNITIVELY NORMAL AND MCI INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P1244.	0.8	0

#	Article	IF	Citations
307	Scientific Autobiography: On Brain Health and Cognitive Fitness Into the Later Years of Lifeâ€"Journey of a Behavioral Neurologist of Aging. American Journal of Geriatric Psychiatry, 2018, 26, 1184-1189.	1.2	0
308	Long-term cognitive decline and mortality after carotid endarterectomy. Clinical Neurology and Neurosurgery, 2020, 194, 105823.	1.4	0
309	Air pollution and plasma amyloid beta: Evidence from the Ginkgo Evaluation of Memory Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
310	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	2.3	0
311	Pattern of Altered Magnetization Transfer Rate in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-13.	2.6	0
312	Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, , 1-8.	2.6	0